{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=37",
    "query": {
      "intervention": "MCG",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 3097,
    "total_pages": 310,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T17:07:39.747Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01543971",
      "title": "Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Miscellaneous Peripheral Blood Cell Abnormalities"
      ],
      "interventions": [
        {
          "name": "TXA127",
          "type": "DRUG"
        },
        {
          "name": "Neupogen (filgrastim)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarix Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2009-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2016-08-31",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543971"
    },
    {
      "nct_id": "NCT00957034",
      "title": "Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "testosterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2009-07",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-01-13",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957034"
    },
    {
      "nct_id": "NCT01623232",
      "title": "MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Vaccines",
        "Aged"
      ],
      "interventions": [
        {
          "name": "MAS-1 adjuvant and influenza HA antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "standard dose, inactivated trivalent influenza vaccine (TIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-10",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2012-09-26",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01623232"
    },
    {
      "nct_id": "NCT04110145",
      "title": "Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Functional Constipation"
      ],
      "interventions": [
        {
          "name": "Linaclotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "2 Years to 5 Years"
      },
      "enrollment_count": 35,
      "start_date": "2019-10-14",
      "completion_date": "2021-04-20",
      "has_results": true,
      "last_update_posted_date": "2022-04-26",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04110145"
    },
    {
      "nct_id": "NCT02301975",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powders via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1526,
      "start_date": "2015-03-01",
      "completion_date": "2016-11-25",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 34,
      "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301975"
    },
    {
      "nct_id": "NCT02276495",
      "title": "Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "ACB Control - 20 ml saline injection for ACB",
          "type": "OTHER"
        },
        {
          "name": "ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block",
          "type": "DRUG"
        },
        {
          "name": "Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2015-01-01",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276495"
    },
    {
      "nct_id": "NCT00873093",
      "title": "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "T-cell Adult Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "L-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "therapeutic hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "High Dose MTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "1 Year to 31 Years"
      },
      "enrollment_count": 148,
      "start_date": "2009-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 157,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00873093"
    },
    {
      "nct_id": "NCT01551316",
      "title": "Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "MN-221",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 2,
      "location_summary": "New Braunfels, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "New Braunfels",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551316"
    },
    {
      "nct_id": "NCT05119855",
      "title": "Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Papillomavirus Infections",
        "Coronavirus Disease (COVID-19)"
      ],
      "interventions": [
        {
          "name": "9vHPV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "9 Years to 11 Years"
      },
      "enrollment_count": 165,
      "start_date": "2022-03-28",
      "completion_date": "2023-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119855"
    },
    {
      "nct_id": "NCT00886626",
      "title": "GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity, Morbid"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "8 Years to 19 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-05",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2012-10-29",
      "last_synced_at": "2026-10-30T17:07:39.747Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00886626"
    }
  ]
}